Document is current
Any future updates will be listed below
-
Authors
Kusuhara, Sentaro https://orcid.org/0000-0002-6458-539X
Sonoda, Koh-Hei https://orcid.org/0000-0002-9819-5509
Kaburaki, Toshikatsu https://orcid.org/0000-0003-1132-6148
Fujita, Tachie
Katayama, Saki
Makishima, Misako
Nakamura, Takao
Nio, Mariko https://orcid.org/0009-0008-5702-0121
Omoto, Takashi https://orcid.org/0000-0002-2120-6839
Matsuo-Tezuka, Yukari
Yoshizaki, Tomoki
Sasaki, Kensuke
Ri, Kairi
Sato, Keiko https://orcid.org/0000-0003-3302-022X
Goto, Hiroshi
-
Funding
Funding for this research was provided by:
Chugai Pharmaceutical Co., Ltd.
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 26 June 2025
First Online: 22 July 2025
Declarations
:
: As the JMDC database comprises de-identified data, informed consent is not required. The study was exempt from review by the Institutional Review Board of the Kobe University Graduate School of Medicine
: Not applicable.
: S.Kusuhara: payment for lectures or supervision from AbbVie GK., AMO Japan K.K., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., Eisai Co., Ltd., Kowa Company, Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Nippon Kayaku, Novartis Pharma K.K., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Viatris Inc.; grants from AMO Japan K.K., Bayer Yakuhin, Ltd., and Chugai Pharmaceutical Co., Ltd.; receipt of drugs from Clinigen K.K.; patent royalties from Charmant, Inc.; K.Sonoda: financial support from AbbVie GK., Alcon Japan Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., HOYA Corporation, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Corporation, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Wakamoto Pharmaceutical Corporation; review panel member for Chugai Pharmaceutical Co., Ltd., Japan Tobacco Inc., Riverfield Corporation, Sand Corporation, Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd.; T.K.: payment for lectures or supervision from AbbVie GK., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., Eisai Co., Ltd., Kowa Company, Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku, Novartis Japan, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd.; grants from AbbVie GK., Alcon Japan Ltd., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., HOYA Corporation, Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd.; receipt of drugs from Kowa Company, Ltd.; T.F., S.Katayama, M.M., T.N., M.N., T.O., Y.T., T.Y.: employees of Chugai Pharmaceutical Co., Ltd.; K.Sasaki, K.R.: employees of Datack, Inc., a paid vendor of Chugai Pharmaceutical Co., Ltd.; indirectly received consulting fees from Chugai Pharmaceutical Co., Ltd. through Datack, Inc.; K.Sato: employee of Third Place, LLC; received consulting fees from Datack, Inc.; H.G.: payment for lectures or supervision from AbbVie GK., Chugai Pharmaceutical Co., Ltd., Kowa Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd.; financial support from AbbVie GK., Alcon Japan Ltd., Chugai Pharmaceutical Co., Ltd., HOYA Corporation, Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd.
